| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3606 | Ndm-1 Inhibitor-2 | Novel Inhibitor of New Delhi Metallo-β-lactamase-1 (NDM-1) |
|
| DCC3607 | nec-1i | Negative control compound for Necrostatin-1 related assays |
|
| DCC3608 | necrostatin-21 | Novel necroptosis inhibitor |
|
| DCC3609 | necrox-18 | Novel inhibitor of caspase-independent cell death with necrotic morphol, distinctly different from apoptosis, autophagy, and necroptosis, displaying strong mitochondrial reactive oxygen species and ONOO- scavenging activity |
|
| DCC3610 | Nefopam | Non-narcotic analgesic for the relief of acute and chronic pain |
|
| DCC3611 | Neil1-in-p2 | Novel Inhibitor of DNA Glycosylases, inhibiting NEIL1 activity |
|
| DCC3612 | Nek2/7-in-51 | Novel ATP-competitive inhibitor of Nek2 and Nek7 |
|
| DCC3613 | Neobractatin | Natural inhibitor of tumor metastasis by upregulating the RNA-binding-protein MBNL2, inducing cell cycle arrest through multiple signaling pathways including RNA binding protein CELF6 |
|
| DCC3614 | neocryptolepine | Inhibitor of the formation of |
|
| DCC3615 | Neothalfine | Potent natural anti-tumor agent against metastatic colorectal cancer, resulting in cell cycle arrest at the G2/M phase and inducing apoptosis through the dysfunction of mitochondria to trigger intrinsic apoptotic pathway by untargeted metabolomic method, |
|
| DCC3616 | Nepetin [520-11-6] | Natural inducer of autophagy and apoptosis, inhibiting glutamate overexcitation and upregulation of the Wnt/β-catenin signaling pathway |
|
| DCC3617 | Neq0502 | Novel AR inhibitor, being selective for the testosterone stimulated AR-dependent prostate cancer cell |
|
| DCC3618 | neq135 | The first potent NAD-driven small molecular inhibitor of TcGAPDH (Trypanosoma cruzi glyceraldehyde 3-phosphate dehydrogenase) |
|
| DCC3619 | nequimed176 | Novel non-peptidic, non-covalent cruzain inhibitor |
|
| DCC3620 | Nesiritide Acetate | Human B-type natriuretic peptide, facilitating cardiovascular fluid homeostasis through counterregulation of the renin-angiotensin-aldosterone system, stimulating cyclic guanosine monophosphate, leading to smooth muscle cell relaxation |
|
| DCC3621 | Nestifylline | Anti-inflammatory, antibronchospastic agent |
|
| DCC3622 | Netarsudil Mesylate | Novel dual Rho Kinase and norepinephrine transporter (ROCK/NET) inhibitor |
|
| DCC3623 | Net-c343 | Novel fluorescent RXR antagonist |
|
| DCC3624 | N-ethylglycine | Lidocaine metabolite, showing antinociceptive effects, inhibiting GlyT1-mediated glycine uptake |
|
| DCC3625 | N-ethylmaleimide | Modulator of the T1007 site, resulting in rapid activation of this transporter and potentiating KCC2 activity |
|
| DCC3626 | Neu321 | Ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth |
|
| DCC3627 | Neu-4854 | Novel potent Trypanosoma brucei Inhibitor |
|
| DCC3628 | Neu617 | Novel inhibitor of the growth of protozoan parasites, against T. brucei bloodstream proliferation |
|
| DCC3629 | Neu-730 | Novel inhibitor of TbrPDEB1, showing modest inhibition of T. brucei proliferation |
|
| DCC3630 | Neurodazole | Novel neurogenic inducer for converting pluripotent P19 cells into electrophysiologically active neurons |
|
| DCC3631 | Neuroprotectant-7 | Novel neuroprotectant for Alzheimers disease, showing significant neuroprotection and antioxidative properties, crossing the blood-brain barrier (BBB) |
|
| DCC3632 | Neurotensin(8-13) | The neurotensin active fragment, eliciting behavioral responses typical of clinically used antipsychotic drugs when administered directly to the brain |
|
| DCC3633 | Nexturastat A-crbn-12d | Novel potent HDAC6 degrader with promising antiproliferation activity in multiple myeloma (MM) cells |
|
| DCC3634 | Nfat-133 | Inhibitor of NFAT-mediated transcription, leading to the suppression of interleukin-2 expression and T cell proliferation, showing immunosuppressive, antidiabetic, and antitrypanosomal activities |
|
| DCC3635 | Nf-kappab Inhibitor-2 | First-in-class inhibitor of NF-κB signaling pathway by preventing the maturation of a rate-limiting multiprotein complex necessary for IKK activation |
|
